We are live on ! Find out more
TXMD icon

TherapeuticsMD
TXMD

56 hedge funds and large institutions have $362M invested in TherapeuticsMD in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

81% more capital invested

Capital invested by funds: $200M → $362M (+$162M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

6% more funds holding

Funds holding: 53 → 56 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.08% less ownership

Funds ownership: 1.04% → 0.96% (-0.08%)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
25
Reduced
10
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$18.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.88M
3
VM
VHCP Management
New York
+$3.71M
4
State Street
State Street
Massachusetts
+$1.66M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$21.3M
2
DM
Deerfield Management
New York
-$3.66M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.54M
4
GPP
Great Point Partners
Connecticut
-$1.22M
5
Deutsche Bank
Deutsche Bank
Germany
-$332K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$9K -$876 -4 -11%
TRCT
52
Tower Research Capital (TRC)
New York
$8K +$6.35K +29 New
FMA
53
FNY Managed Accounts
New York
$3K +$2.19K +10 New
U
54
UBS
Switzerland
$2K +$1.53K +7 New
Manulife (Manufacturers Life Insurance)
55
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$334 +$22.6K +103 +9%
DM
56
Deerfield Management
New York
– -$3.66M -25,000 Closed
GPP
57
Great Point Partners
Connecticut
– -$1.22M -8,333 Closed
UOC
58
UBS O'Connor
Illinois
– -$293K -2,000 Closed
WC
59
Wexford Capital
Florida
– -$220K -1,500 Closed
ProShare Advisors
60
ProShare Advisors
Maryland
– -$144K -986 Closed
SO
61
STRS Ohio
Ohio
– -$80K -546 Closed
SG Americas Securities
62
SG Americas Securities
New York
– -$45K -309 Closed
JP Morgan Chase
63
JP Morgan Chase
New York
– -$32K -217 Closed
VKH
64
Virtu KCG Holdings
New York
– -$31K -215 Closed
Wells Fargo
65
Wells Fargo
California
– -$29K -198 Closed
Ameriprise
66
Ameriprise
Minnesota
– -$21.2K -97 -99%
California Public Employees Retirement System
67
California Public Employees Retirement System
California
– -$10K -68 Closed
Royal Bank of Canada
68
Royal Bank of Canada
Ontario, Canada
– -$1K -8 Closed
1 2
3

TXMD Hedge Fund Activity: Q4 2013 in Review

56 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2013, worth a combined $362M — up 81% from $200M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TXMD positions and 12 closed out — a net gain of 3 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $18.7M. The largest seller was RA Capital Management, cutting an estimated $21.3M.

  • 56 institutional investors held TherapeuticsMD (TXMD) as of Q4 2013, up from 53 in Q3 2013.
  • Funds reported $362M of TherapeuticsMD stock for Q4 2013, up 81% quarter-over-quarter.
  • 15 funds opened new TherapeuticsMD positions in Q4 2013 and 12 closed out, a net change of +3 holders.
  • The largest TherapeuticsMD buyer in Q4 2013 was Gilder Gagnon Howe & Co, an estimated $18.7M added.
  • The largest TherapeuticsMD seller in Q4 2013 was RA Capital Management, an estimated $21.3M sold.

Based on aggregated 13F filings for Q4 2013.